Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ferrer Submits IND for Arasertaconazole Nitrate

Published: Tuesday, January 01, 2013
Last Updated: Monday, December 31, 2012
Bookmark and Share
Phase III studies in VVC for the patented, best-in-class topical azole will be initiated at the beginning of 2013, subject to regulatory approval.

Ferrer has announced that it has filed an IND for its topical antifungal agent Arasertaconazole nitrate.

The agent has recently demonstrated rapid symptomatic relief and significant clinical and mycological benefits after a single administration delivered as a vaginal suppository (pessary) formulation in a multicentre Phase II study in patients with VulvoVaginal Candidiasis (VVC).

VVC, or vaginal thrush as it is also known, is a common infection affecting 70 - 75 per cent of women at least once in their lives. The worldwide market for gynaecological antifungal products exceeds USD 600 million per annum.

Arasertaconazole is a new, fast-acting topical antifungal. The agent has a broad spectrum of activity against Candida spp involved in VVC, including species described as resistant to fluconazole.

It is the active, patented, R-enantiomer of sertaconazole nitrate, itself an antifungal agent developed by Ferrer and marketed for more than 20 years in more than 70 countries.

Formulated as a vaginal suppository (pessary), Arasertaconazole has demonstrated very low systemic exposure, a good safety profile and was well tolerated in clinical studies involving 283 female subjects to date.

In the multicentre Phase II dose-ranging study involving 229 female patients with VVC, Arasertaconazole formulated as a vaginal suppository (pessary) demonstrated both fast-acting (superiority to placebo at 8 plus/minus 2 days of treatment) and prolonged (up to at least 26 plus/minus 4 days) clinical and mycological efficacy at all doses tested (150mg, 300mg, 600mg).

The therapeutic response to Arasertaconazole was dose-dependent, with the 600mg dose most efficacious.

Moreover, Arasertaconazole showed evidence of rapid relief from additional clinical symptoms (at less than 2 days, e.g. irritation and itching) when compared to placebo. Arasertaconazole was both safe and well tolerated in this study.

"VulvoVaginal Candidiasis (VVC) due to Candida spp infections remains a common problem worldwide, especially in women of childbearing age. The emergence of both treatment resistant Candida species and new pathogenic strains are considered some of the reasons for the underserved medical needs in this condition," said Antonio Guglietta, R&D Director at Ferrer.

Guglietta continued, "Following discussions with the regulators, Ferrer will initiate Phase III clinical studies that will further differentiate Arasertaconazole as a safer, fast-acting antifungal treatment for VVC in women aged more than 12 years old."

Ferrer is currently assessing alternative formulations for Arasertaconazole as treatments for other topical fungal infections that include tinea pedis (athlete's foot).

Arasertaconazole, as well as the vaginal suppository (pessary) formulation, is the subject of granted and pending patent applications and is available for further development and commercialization worldwide from Ferrer.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Designer Cell Fate Switches Could Streamline Stem Cell Biology
Researchers develop new method of reprogramming cells between cell types in a more efficient way than before.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
More Effective Strategy for Producing Flu Vaccines
Researchers have developed a virus backbone, allowing producers to grow vaccine viruses in mammalian cells, rather than in eggs.
Soil Carbon Release Might Equal U.S. Emissions
Research suggests 55M tons of carbon will be release from soils by 2050, 17% higher than prjected emissions.
Inspiring Futuristic Innovation: Brain ‘Organoids’
Scientists create artificial brains, providing an advanced model for studying brain tumour development.
Predicting Leukaemia Development in Cancer Patients
Biomarker may predict which formerly treated cancer patients will develop highly fatal form of leukemia.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!